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Abstract
Genes involved in cholesterol biosynthesis and uptake are transcriptionally regulated in response to cellular sterol content
in a coordinated manner. A number of these genes, including 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)
and LDL receptor (LDLR), undergo alternative splicing, resulting in reductions of enzyme or protein activity. Here we
demonstrate that cellular sterol depletion suppresses, and sterol loading induces, alternative splicing of multiple genes
involved in the maintenance of cholesterol homeostasis including HMGCR and LDLR, the key regulators of cellular
cholesterol biosynthesis and uptake, respectively. These changes were observed in both in vitro studies of the HepG2
human hepatoma derived cell line, as well as in vivo studies of St. Kitts vervets, also known as African green monkeys, a
commonly used primate model for investigating cholesterol metabolism. These effects are mediated in part by sterol
regulation of polypyrimidine tract binding protein 1 (PTBP1), since knock-down of PTBP1 eliminates sterol induced changes
in alternative splicing of several of these genes. Single nucleotide polymorphisms (SNPs) that influence HMGCR and LDLR
alternative splicing (rs3846662 and rs688, respectively), have been associated with variation in plasma LDL-cholesterol
levels. Sterol-induced changes in alternative splicing are blunted in carriers of the minor alleles for each of these SNPs,
indicating an interaction between genetic and non-genetic regulation of this process. Our results implicate alternative
splicing as a novel mechanism of enhancing the robust transcriptional response to conditions of cellular cholesterol
depletion or accumulation. Thus coordinated regulation of alternative splicing may contribute to cellular cholesterol
homeostasis as well as plasma LDL levels.
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Introduction
Alternative splicing, the post-transcriptional editing process that
can generate multiple mRNAs from a single gene, was once
considered to be primarily a means of generating protein diversity
[1]. However, more recently its role as a mechanism of regulating
gene expression has been appreciated [2]. Functionally relevant
alternative splicing has been reported in several genes involved in
cellular cholesterol production and uptake [3,4,5,6,7,8]. The gene
encoding 3-hydroxy-3-methylglutaryl coenzyme A reductase
(HMGCR), the enzyme that catalyzes the rate limiting step of
cholesterol biosynthesis, undergoes alternative splicing of exon 13.
Exon 13 skipping impairs enzymatic activity [3,4], and also results
in reduction of its sensitivity to inhibition by statins, a class of
cholesterol lowering drugs that act as competitive inhibitors of
HMGCR [4]. The LDL receptor (LDLR), which is primarily
responsible for cellular uptake of LDL from plasma, has several
splice variants, the two most common of which involve exon
skipping: LDLR4(-) and LDLR12(-), respectively. Both have been
shown to be associated with reduced LDLR cell surface protein
and LDL internalization, as well as hypercholesterolemia [6,8].
Proprotein convertase subtilisin/kexin type 9 (PCSK9), which
binds to the LDLR protein and induces its degradation, has a
minor splice variant lacking exon 8 (PCSK9 8(-)) that has no effect
on LDLR protein turnover [5]. HMG-CoA synthase (HMGCS1),
which catalyzes the reaction immediately before HMGCR, has a
highly complex 59 UTR that regulates translational efficiency and
undergoes exon 2 skipping [7]. Mevalonate kinase, encoded by
MVK, catalyzes the step immediately following HMGCR, and
undergoes alternative splicing of exon 4 and/or 5, both of which
disrupt the open reading frame [9]. Both HMGCR exon 13
skipping and LDLR exon 12 skipping are influenced by cis-acting
SNPs [3,4,6] that have been found in genome-wide association
analysis (GWAS) to contribute to inter-individual variation in
plasma LDL-cholesterol in multiple independent populations
[3,6,10,11]. These findings suggest that alternative splicing of
genes involved in cholesterol biosynthesis and receptor-mediated
uptake has physiologically relevant effects on plasma LDL-
cholesterol.
Polypyrimidine tract binding protein (PTBP1) antagonizes the
function of the essential splicing factor U2AF in the recognition of
the 39 splice site [12], and thus acts as a negative splicing regulator
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19420of numerous pre-mRNAs [13,14,15]. PTBP1 has been postulated
to modulate LDLR mRNA stability by binding to the 39 UTR [16],
and therefore it is possible that such an interaction may also
influence alternative splicing.
Since HMGCR, LDLR, HMGCS1, MVK and PCSK9 are among
the genes whose transcription is regulated in a coordinated fashion
by SREBP in response to sterols [17,18], we sought to determine if
the relative levels of the alternatively spliced versus full-length
transcripts are also subject to sterol regulation. Here we provide
evidence that the relative amounts of alternatively spliced
transcripts of HMGCR, LDLR, HMGCS1, MVK and PCSK9 in
hepatocytes (HepG2), human immortalized lymphoblast cell lines,
and livers from cholesterol-fed African Green monkeys, are
reduced under conditions of sterol depletion, and induced under
conditions of sterol loading. These results implicate alternative
splicing in the coordinated regulation of expression of genes
involved in cholesterol biosynthesis and uptake.
Results
The relative expression level of alternatively spliced to
full-length HMGCR is sterol regulated
To determine if the ratio of HMGCR alternatively spliced to
full-length transcripts is sterol regulated, both the full-length
transcript, HMGCR13(+), and the alternatively spliced form,
HMGCR13(2), were measured in HepG2 and IMR-90 cells
after sterol depletion by 24 hour incubation with varying
concentrations of simvastatin (0.1 to 50 mM), and 10%
lipoprotein deficient serum (LPDS). As shown in Figure 1A,
extreme cholesterol depletion (statin + LPDS) of IMR-90 cells
up-regulated both HMGCR13(+) and 13(2) transcripts, howev-
er, the relative induction of HMGCR13(2) was substantially
lower than the 13(+) transcript. Since quantitative real time
PCR has a much larger dynamic range for quantitation of
mRNA transcripts compared to measurements of band density,
all subsequent transcript quantification was performed by splice
variant-specific real time PCR as described in the Methods.
Cholesterol depletion of HepG2 cells induced HMGCR13(2)
16–31% (20% average) less than the 13(+) transcript, p=0.036
(Figure 1B). In addition, provision of LDL-derived cholesterol
to HepG2 cells incubated with 0.5 mM simvastatin (Figure 1C)
resulted in 10–17% (12% average) greater suppression of the
HMGCR13(+) transcript in comparison to the HMGCR13(2)
transcript (p=0.049), suggesting that sterol loading induced
HMGCR alternative splicing. These effects were confirmed in 26
immortalized lymphoblast cell lines incubated with either 10%
FBS, 10% LPDS, 0.5 mM simvastatin, 0.5 mM simvastatin +
10% LPDS, or 1 mg/ml 25-hydroxycholesterol + 10% LPDS. As
shown in Figure 1D, HMGCR13(2) was induced 15% less than
the HMGCR13(+) transcript in the simvastatin incubated cells
lines, and 25% less in the simvastatin + LPDS incubated cells,
while sterol loading with 25-hydroxycholesterol suppressed
HMGCR13(2) 34% less than the 13(+) transcript (p,0.0001
for each treatment). Suppression of HMGCR alternative splicing
with extreme sterol depletion (statin + LPDS) was also
confirmed in freshly isolated peripheral blood mononuclear
cells (n=7, data not shown) demonstrating that this phenom-
enon is not unique to transformed cells.
Sterols regulate the relative ratio of alternatively spliced
to full-length transcripts in multiple genes involved in
cholesterol biosynthesis and uptake
Given the strong evidence for sterol regulation of HMGCR
splice variants, we tested whether there are also sterol-regulated
changes in the relative amounts of alternatively spliced to full-
length transcripts of other key regulatory genes involved in
cholesterol metabolism - LDLR, HMGCS1, MVK,a n dPCSK9.
HepG2 cells were incubated with 2.0 mMs i m v a s t a t i n+ 10%
LPDS or sham buffer + 10% FBS for 24 hours, after which
either 50 mg/ml LDL-cholesterol or 1 mg/ml 25-HC were
added and incubated for an additional 24 hours. These genes
are known to be transcriptionally responsive to sterols [17], and
as expected, expression of each was up-regulated by statin
exposure, effects that were reversed by the addition of LDL-
cholesterol or 25-HC (data not shown). Similar to
HMGCR13(2), all splice variants of these genes -LDLR4(2),
LDLR12(2), MVK4(2), HMGCS1 2(2),a n dPCSK9 8(2) -
showed evidence of sterol regulation (Figure 2A). Sterol
depletion suppressed the relative amounts of alternatively
spliced to full-length transcripts by 8–50%, while addition of
either LDL-cholesterol or 25-hydroxycholesterol increased these
ratios by 16–124% in comparison to standard culture conditions
(10% FBS). These phenomena were confirmed in immortalized
lymphoblast cell lines (n=6, data not shown).
Sterol regulation of mRNA stability does not differ
between full-length and alternative spliced transcripts
To determine if sterol-induced changes in the ratios of
alternative spliced to full-length transcripts were due to
transcript-specific differences in mRNA decay rates, HepG2
cells were pre-incubated with either 2.0 mM simvastatin + 10%
LPDS or sham buffer + 10% FBS for 24 hours, after which
1 mg/ml actinomycin D was added to the media (n=12
experiments). Although statin treatment did not affect stability
of the HMGCR13(2) transcript, the half-life of the HMGCR
13(2) transcript was 53% lower than in the sham treated
sample (6.260.4 hr versus 11.860.6 hr respectively,
p,0.00001, Figure 2B). Sterol depletion also increased the
half-life of the LDLR4(+) transcript (1.160.1 hr sham versus
1.560.1 hr statin, p=0.0007) but did not affect stability of the
LDLR4(2) transcript. These results indicate that differential
changes in message stability of LDLR4(2) and HMGCR13(2) in
comparison to their full length counterparts following statin
treatment may contribute to a relative reduction in their
cellular levels. In contrast, there were no changes in transcript
half-life of MVK4(+), MVK4(2), LDLR12(+) or LDLR12(2).
Paradoxically, both the full length HMGCS1 and PCSK9
transcripts had significantly reduced transcript half-lives after
sterol depletion while there was no change in mRNA stability of
their respective alternatively spliced variants. These results
strongly suggest that the sterol-induced changes in the ratio of
alternative spliced to full-length HMGCS, MVK, LDLR12, and
PCSK9 are not due to splice variant specific differences in
transcript stability.
LDLR alternative splicing is induced in cholesterol fed
African Green monkeys
To determine if the splice variants of interest were expressed in
liver from the African Green monkey, we used RT-PCR with
primers spanning the alternatively spliced exons of interest, and
DNA sequencing, to identify and confirm expression of HMGCS1
2(2), MVK4(2), LDLR4(2), LDLR12(2), and PCSK9 8(2),
(Figure 3a). HMGCR13(2) was not detected. The splice variants
were quantified along with the HMGCS1 2(+), MVK4(+),
LDLR4(+), LDLR12(+) and PCSK9 8(+) transcripts in liver biopsies
of monkeys fed either a cholesterol-supplemented or control diet.
As expected, all transcripts were down-regulated by cholesterol
Coordinately Regulated Alternative Splicing
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were suppressed less than their full-length counterparts (p,0.05,
n=28, Figure 3b). Although HMGCS1 2(2) and LDLR12(2)
also appeared to be suppressed less than HMGCS1 2(+) and
LDLR12(+), these differences did not achieve statistical signifi-
cance. Additional analyses suggested a correlation of change in
hepatic total cholesterol and cholesterol ester content with the
magnitude of change in alternative splicing, in that animals with
greater increases in hepatic total cholesterol and cholesterol ester
also had greater increases in % LDLR12(2) (Figure S1).
Alternative splicing is not regulated by non-sterol end-
products of the mevalonate pathway
Since statin treatment blocks production of both cholesterol and
other non-sterol end-products of the mevalonate pathway such as
isoprenoids, we sought to determine if changes in alternative
splicing are mediated primarily by one or more of these end-
products. Because non-sterol regulation of HMGCR has tradi-
tionally been studied in fibroblasts [19], we incubated early
passage normal human diploid fibroblasts (IMR-90) for 24 hours
with 2.0 mM simvastatin + 10% LPDS in duplicate, after which
Figure 1. HMGCR alternative splicing is sterol regulated. A) Fold change in HMGCR13(+) and 13(2) transcripts with conditions of sterol
depletion. IMR-90 cells were incubated with varying concentrations of activated simvastatin in the absence of exogenous cholesterol for 24 hours.
RT-PCR with primers spanning exons 12 to 14 was used to amplify both the HMGCR13(+) and 13(2) transcripts, and band density was quantified. One
representative sample is shown. B) Fold change in HMGCR transcript with conditions of sterol depletion. HepG2 cells were incubated with varying
concentrations of activated simvastatin in the absence of exogenous cholesterol for 24 hours, and changes in transcript levels were quantified by real
time PCR using splice variant specific assays, n=8. C) Fold change in HMGCR transcript with condition of sterol loading. HepG2 cells were incubated
with 0.5 mM simvastatin with varying concentrations of LDL-cholesterol for 24 hours and changes in transcript levels were quantified by real time
PCR, n=8. D) Fold change in HMGCR transcript with varying conditions of sterol depletion and loading. Immortalized lymphoblast cell lines were
incubated with either 10% FBS (control), 10% LPDS, 0.5 mM simvastatin + 10% FBS, 0.5 mM simvastatin + 10% LPDS or 1 mg/ml 25-hydroxycholesterol
+ 10% LPDS for 24 hours, n=26. HMGCR transcripts were quantified by real time PCR and fold change was calculated from the 10% FBS incubated
samples. Repeated measures MANOVA was used to identify statistical significance in the difference in fold changes between the 13(+) and 13(2)
transcripts across the different incubation conditions (A) and (B), and paired t-tests were used to identify statistically significant differences in fold
changes of HMGCR13(+) versus 13(2) per incubation condition (C). Values plotted are mean 6 s.e.m.
doi:10.1371/journal.pone.0019420.g001
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10 mM mevalonate was added to one set of cell lines, while the
other received an additional dose of cholesterol, and aliquots were
removed over the course of 6 hours. As expected, HMGCR13(+)
transcript levels did not differ between the cell lines treated with
LDL-C alone versus those treated with LDL-C plus mevalonate
(Figure 4), consistent with previous reports that HMGCR tran-
scriptional regulation is mediated by sterols and not by non-sterol
products of the mevalonate pathway [20]. HMGCR13(2) transcript
levels were also unchanged by the addition of mevalonate,
indicating that statin suppression of HMGCR alternative splicing is
regulated by changes in sterol production. Furthermore, there was
no evidence for non-sterol regulation of amounts of either
LDLR4(2) or 12(2) (data not shown), suggesting that sterols are
responsible for coordinated changes in alternative splicing of genes
involved in cholesterol metabolism.
Figure 2. Multiple genes involved in regulating cholesterol homeostasis are subject to sterol regulated alternative splicing. A)
HepG2 cells were incubated with either 2.0 mM simvastatin +10% LPDS or sham buffer with 10% FBS. After 24 hours, either 50 mg/ml LDL-cholesterol
or 1 mg/ml 25-HC were added to the statin treated sample and incubated for an additional 24 hours, n=6. Fold changes were calculated from the
cells incubated with 10% FBS only. B) Splice variant specific changes in transcript half-life in response to sterol depletion. HepG2 cells were incubated
with either 2.0 mM simvastatin + 10% LPDS or sham buffer with 10% FBS in replicate 6-well plates. After 24 hours, 1 mg/ml Actinomycin D was added,
and individual wells were collected after 0, 0.5, 1, 2, 4, 6, 24 and 48 hours, n=12. mRNA quantity values were log transformed and plotted versus
time. Linear regression was used to calculate the slope of the resulting line, and mRNA half-life was calculated as: t1/2 (h) = ln2/(22.3036slope).
P-values were calculated as paired two tailed t-tests. Values plotted are mean 6 s.e.m.
doi:10.1371/journal.pone.0019420.g002
Coordinately Regulated Alternative Splicing
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19420Sterol regulation of splicing occurs prior to
transcriptional response
Although pre-mRNA spicing and transcription are related
processes, we sought to determine if there was evidence for
regulation of alternative splicing prior to a detectable change in
overall transcription. HMGCR13(+) and 13(2) transcripts were
quantified in HepG2 incubated with either 2.0 mM simvastatin +
10% LPDS or sham buffer + 10% FBS over the course of 6 hours
(n=5) (Figure 5). Decreased %HMGCR13(2) occurred within
30–45 minutes as a result of up-regulation (1.360.16 fold) of the
HMGCR13(+) transcript with a corresponding down-regulation
(0.960.05 fold) of the HMGCR13(2) transcript. This effect
subsided within 2 hours post-exposure and was followed by a
second phase of transcriptional up-regulation of both
HMGCR13(+) and 13(2). Similar results were obtained with
immortalized lymphoblast cell lines (n=6, data not shown). This
early change in alternative splicing was not seen for LDLR exon 4
or 12 skipping, or for MVK exon 4 skipping (data not shown).
Sterol regulated alternative splicing varies in a
coordinated fashion among individuals
In 24 immortalized lymphoblast cell lines incubated with either
2.0 mM simvastatin or sham buffer there was a positive correlation
between magnitude of change in %HMGCR13(2) and
%LDLR12(2) (p=0.02, r
2=0.21) and a weaker although non-
significant (p=0.19) relationship between %HMGCR13(2) and
Figure 3. Validation of sterol-induced changes in alternative splicing in cholesterol fed African Green monkeys. A) RT-PCR was
performed with primers spanning alternatively spliced exons in HMGCS1, HMGCR, MVK, LDLR and PCSK9 with cDNA derived the liver of an African
Green monkey or HepG2 cell line (human control). *The PSCK9 8(2) and MVK4(2) transcripts are minor species in humans and monkeys respectively
and difficult to visualize via RT-PCR, thus PCR was performed using primers that specifically amplify the alternatively spliced transcripts. B) Full length
and alternative spliced HMGCS1, MVK, LDLR and PCSK9 transcripts were quantified in liver biopsies obtained from monkeys with (n=28) and without
(n=23) cholesterol supplementation. Fold changes were calculated for each cholesterol fed animal as the transcript quantity value divided by the
average of all control diet fed animals. Paired t-tests were used to identify statistically significant differences in the magnitude of fold change of the
full-length versus alternatively spliced transcripts. **Indicates p,0.05. Values plotted are mean 6 s.e.m.
doi:10.1371/journal.pone.0019420.g003
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%HMGCR13(2) fold change and either LDLR12(+) or 4(+) fold
change (data not shown).
A similar correlation in the degree of induction of HMGCR and
LDLR alternative splicing was seen after sterol loading in 31
lymphoblast cell lines incubated with 1 mg/ml 25-hydroxycholes-
terol. As expected, %HMGCR13(2), %LDLR12(2) and
%LDLR4(2) were up-regulated by sterol loading (1.560.1 fold,
1.560.1 and 1.260.1 fold respectively). The changes in
%HMGCR13(2) and %LDLR4(2) were correlated (p=0.036,
Figure 6) with a weaker and non-significant (p=0.17) relation-
ship between %HMGCR13(2) and %LDLR12(2). Again, there
was no relationship between %HMGCR13(2) fold change and
either LDLR4(+) or 12(+) fold change.
PTBP1 mediates sterol regulated changes in alternatively
spliced transcripts
PTBP1 is a splicing regulator that promotes alternative splicing
[13,14,15] and has been previously shown to bind the LDLR
transcript [16]. Since changes in alternative splicing appear to be
coordinately regulated, we tested if PTBP1 influences alternative
splicing of LDLR as well as other genes involved in cholesterol
biosynthesis and uptake, HepG2 cells were transfected with a
Silence Select siRNA specific for PTBP1 or a non-targeting
negative control, and splice variants were quantified by qPCR
(n=24). Transfection with the PTBP1 specific siRNA reduced
PTBP1 gene expression by 68.060.03%, and protein expression
by 66% (Figure 7A). PTBP1 knock-down resulted in reduction of
the relative levels of LDLR4(2), LDLR12(2), HMGCS1 2(2),
MVK4(2), and PCSK9 8(2) by 9–23%, (p,0.05, Figure 7B). The
non-targeting siRNA did not affect PTBP1 gene expression or
alternative splicing of any of the genes tested (data not shown).
Interestingly, HMGCR13(2) was unchanged by PTBP1 knock-
down, indicating that this splicing event is regulated by other
mechanisms.
Since PTBP1 binding to the LDLR 39 UTR has been shown to
regulate the half-life of several transcripts [16], we sought to
determine if the changes in the relative abundance of alternatively
spliced transcripts after PTBP1 knock-down were due to transcript
Figure 4. Statin induced changes in HMGCR alternative splicing
are sterol mediated. IMR-90 cells were incubated with 10% LPDS for
24 hours in duplicate, after which 2.5 mM simvastatin was added to the
media. After 24 hours, 50 mg/ml LDL-cholesterol was added and
incubated for an additional 24 hours. 10 mM mevalonate was added
to one set of cells, while 50 mg/ml LDL-cholesterol was added to the
second set of cells. Aliquot were removed after 1, 2, 4 and 6 hours, and
HMGCR13(+) and 13(2) was quantified by qPCR. The entire experiment
was performed in triplicate. Values plotted are mean 6 s.e.m.
doi:10.1371/journal.pone.0019420.g004
Figure 5. Transcriptional versus splicing regulation in HepG2
cells. Time course analysis of HMGCR gene expression in HepG2 cells
incubated with 2.0 uM simvastatin +10% LPDS, or placebo + 10% FBS,
n=5. Change in HMGCR alternative splicing occurs within 30 min
minutes post-treatment as indicated by an immediate down-regulation
of HMGCR13(2), open circles, and corresponding up-regulation of
HMGCR13(+), solid circles. Data were calculated as the ratios of the fold
changes of the statin versus placebo treated sample at each individual
time point in comparison to 0 minutes. Values plotted are mean 6
s.e.m.
doi:10.1371/journal.pone.0019420.g005
Figure 6. Sterol induced changes in HMGCR and LDLR alterna-
tive splicing are correlated. Immortalized lymphoblast cell lines
were incubated for 24 hours with either 1 mg/ml 25-hydroxycholesterol
+ 10% LPDS or standard culture conditions (10% FBS), n=31. Fold
changes were calculated as percent alternative spliced in the 25-HC
treated sample divided by the 10% FBS treated sample, and statistical
significance was calculated using linear regression.
doi:10.1371/journal.pone.0019420.g006
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transfected with either the non-targeting control or PTBP1-
specific siRNA for 18 hrs, and subsequently treated with
actinomycin D (n=12). There were no splice variant-specific
differences in transcript stability with PTBP1 knock-down (Figure
S2), indicating that the changes in the relative ratios of
alternatively spliced to full-length transcripts were most likely
due to direct effects on alternative splicing of these genes.
Sterol regulation of PTBP1 was assessed in HepG2 cells exposed
to sterol depletion for 24 hours after which either LDL-cholesterol
or 25-hydroxycholesterol was added (conditions described in
Figure 2). PTBP1 mRNA expression was reduced to 0.660.2 fold
of control by sterol depletion (statin + LPDS), while incubation
with sterols reversed this effect by up-regulating PTBP1 4.160.1
fold (Figure 7C), demonstrating that PTBP1 is transcriptionally
responsive to sterols.
Figure 7. PTBP1 mediates sterol regulation of alternative splicing of genes involved in cholesterol biosynthesis and uptake. A)
Representative western blot of HepG2 cells before and after 18 hr transfection with PTBP1 Silence Select siRNA. B) Effect of PTBP1 knock-down on the
relative ratios of full-length to alternatively spliced transcripts. HepG2 cells were transfected with either PTBP1 Silence Select siRNA or a non-targeting
siRNA control for 18 hours, n=12 Fold changes were calculated as percent alternatively spliced in the cells transfected with the PTBP1 specific siRNA
divided by the percent alternatively spliced in cells transfected with the non-targeting negative control. C) HepG2 cells were treated as described in
Figure 3. Fold change in PTBP1 gene expression was calculated from cells incubated with sham buffer + 10% LPDS. Statistically significant differences
were calculated using two-tailed paired t-tests, n=6. D) HepG2 cells were transfected with either a siRNA targeted to PTBP1 or a non-targeting
negative control in duplicate. After 18 hours, incubation media was refreshed to include either 2.0 mM simvastatin + 10% LPDS or sham buffer + 10%
FBS and cells were incubated for an additional 24 hours, n=6. Statin induced fold changes in percent alternatively spliced were calculated
independently in the PTBP1 siRNA versus non-targeting negative control samples as the value measured in the statin incubated sample divided by
the value measured in the sham incubated sample. All values shown are mean 6 s.e.m. FL = full length.
doi:10.1371/journal.pone.0019420.g007
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alternative splicing, HepG2 cells were incubated with either a
siRNA specific for PTBP1 or a non-targeting negative control for
18 hours, after which either 2.0 mM simvastatin or placebo was
added for an additional 6 hours (n=9). PTBP1 knock-down
attenuated the suppression of alternative splicing with sterol
depletion (Figure 7D). The ratios of alternatively spliced to full-
length transcripts of HMGCS1, LDLR and MVK were reduced in
the cells transfected with the non-targeting siRNA after sterol
depletion, but not after PTBP1 knock-down. Notably, sterol
induced changes in HMGCR13(2)/13(+) or PCSK9 8(2)/8(+)
were not affected by PTBP1 knock-down. PTBP1 knock-down
also attenuated statin-induced transcriptional up-regulation of
HMGCS, MVK and LDLR12(+), but had no effect on LDLR4(+)
(Figure S3). Taken together, these results demonstrate that sterol
induced changes in the relative levels of alternatively spliced to full
length transcripts in multiple genes is mediated in part by down-
regulation of PTBP1.
Sterol depletion and loading blunts genetic regulation of
HMGCR and LDLR alternative splicing
Although statin treatment suppresses both HMGCR13(2) and
LDLR12(2) alternative splicing, the absolute amount of these
transcripts expressed after statin incubation vs. baseline remains
tightly and positively correlated among immortalized lymphoblast
cell lines (p,0.0001, r
2=0.70, n=173 and p,0.0001, r
2=0.63,
n=251 respectively). This suggests intrinsic differences in factors
regulating alternative splicing of these genes among the cell lines.
Since both HMGCR13(2) and LDLR12(2) are genetically
regulated by cis-acting SNPs (rs3846662 and rs688 respectively
[3,4,6]), we tested for interactions between genetic and non-
genetic regulation of alternative splicing. Interestingly there
appears to be an interaction between HMGCR rs3846662, the
intron 13 SNP known to directly influence exon 13 alternative
splicing [3,4], and the degree of statin suppression of exon 13
skipping, since this phenomenon was only seen in cell lines that
carry at least one copy of the ‘‘A’’ allele of rs3846662 (Figure 8A).
Consequently, the relationship between rs3846662 and
%HMGCR13(2) expression was blunted by statin treatment
(interaction p,0.0001, Figure 8B). Similar results were seen
with rs688, an exon 12 SNP that regulates LDLR exon 12
alternative splicing, and %LDLR12(2), where sterol suppression of
exon 12 skipping occurred only in cell lines with at least one copy
of the ‘‘T’’ or minor allele (Figure 8C). Using a dominant genetic
model, rs688 genotype remained significantly associated with
%LDLR12(2) after statin treatment, however this relationship was
attenuated compared to that with baseline %LDLR12(2)
(Figure 8D). Given the sterol by genotype interaction in
regulation of alternative splicing, we genotyped the HepG2 cell
line and found that it was heterozygous for the minor allele of
rs3846662 (A/C) and homozygous for the major allele of rs688
(C/C).
Discussion
The genes involved in cellular cholesterol biosynthesis and
uptake are known to be coordinately regulated by the SREBP/
Insig/SCAP system in response to sterols such that these pathways
are induced and suppressed as a whole [17]. Here we provide
evidence that orchestrated regulation of HMGCR and LDLR, the
two key regulatory genes responsible for cholesterol biosynthesis
and uptake, respectively, also occurs at the level of alternative
splicing. Furthermore, other genes in the pathway of cholesterol
biosynthesis including HMGCS1 and MVK, as well as another key
gene involved in cholesterol uptake, PCSK9, are subject to similar
regulation, suggestive of a pathway level effect. Although
coordinated regulation of the cholesterol biosynthetic pathway
has also been seen at the level of enzyme activity and/or protein
amount [21,22,23,24], these changes have been attributed largely
to mechanisms that influence protein synthesis such as SREBP-
induced gene expression. Coordinated regulation of pre-mRNA
splicing of multiple genes by an external stimulus has been recently
demonstrated in the case of insulin, which has been found to affect
splicing of over 150 genes [25]. Moreover, orchestrated changes in
alternative splicing have been shown in several biological processes
including apoptosis [26].
Alternative splicing of HMGCR, LDLR, MVK, and PCSK9
reduces protein or enzyme activity [3,4,5,6,8,9,27,28,29]. In
addition, we found here that alternative splicing of the 59 UTR
of HMGCS1 reduces the half-life of the transcript, consistent with
the likelihood that this process also results in decreased HMGCS1
protein levels. We found that cellular cholesterol deficiency
reduced the ratio of alternatively spliced to full-length transcripts
(increasing enzyme or protein activity) while cholesterol accumu-
lation increased this ratio (decreasing enzyme or protein activity).
These data strongly suggest that modulating the ratio of full-length
to alternatively spliced transcripts is a generalized mechanism for
regulating expression of genes involved in cholesterol biosynthesis
and uptake. Moreover, we found evidence for in vivo operation of
this mechanism by showing that cholesterol feeding influences
alternative splicing of hepatic HMGCS1, MVK, LDLR and PCSK9
in African Green monkeys. Although in vivo sterol regulation of
HMGCR13(2) could not be confirmed in this species due to lack of
detectable hepatic expression, we have identified its presence in
other non-human primates (personal communication M.W.M).A s
described in the supplementary material, the association of the
magnitude of alternative splicing with hepatic content of
cholesterol ester but not free cholesterol likely represents the role
of the former as the storage form of excess diet-derived cholesterol,
while multiple homeostatic mechanisms operate to limit increases
in cellular free cholesterol.
Co-regulation of alternative splicing of multiple genes in
pathways affecting cholesterol metabolism may provide a means
to quickly modulate or fine-tune the effects of SREBP-mediated
transcriptional regulation of intracellular cholesterol content.
Indeed, our results demonstrate that sterol-induced changes in
HMGCR alternative splicing can occur prior to detectable
transcriptional response. Although our incubations with IMR-90
fibroblasts suggest that HMGCR alternative splicing is not
regulated by non-sterol end-products of the mevalonate pathway,
these results do not exclude the possibility of more immediate
regulation (within 45 minutes post-treatment) of HMGCR
alternative splicing by products other than cholesterol generated
from the mevalonate pathway.
Coordinated regulation of alternative splicing across multiple
genes suggests that there are shared mechanisms responsible for
generating this response. One possibility for such a mechanism is
suggested by our finding that siRNA knockdown of PTBP1, an
RNA binding protein and negative splicing regulator previously
shown to bind the LDLR gene [16], reduces the relative levels of
LDLR, HMGCS1, MVK, and PCSK9 splice variants. Although these
changes were relatively modest, it was recently reported that
siRNA knock-down of PTBP1 results in the up-regulation of
PTBP2. Since PTBP1 and PTBP2 have similar functional effects,
dramatic changes in splicing are seen only when both PTBP1 and
PTBP2 are knocked down [30]. Thus, our results indicate that
modulation of PTBP1 reduces the level of alternatively spliced
mRNA despite the compensatory up-regulation of PTBP2, which
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depletion (personal communication, M.W.M. and F.G.). Moreover, the
attenuation of HMGCS1, MVK and LDLR12(+) transcriptional
response to statin after PTBP1 knock-down suggests that these
genes are also subject to transcriptional regulation by PTBP1,
consistent with previous reports that PTBP1 can bind and activate
promoters [31,32]. However, the specificity of this activity is
different from its effects on mRNA stability, as demonstrated by
the robust effects of PTBP1 knock-down on LDLR exon 4 skipping,
but not on statin-induced expression of the LDLR4(+) transcript.
We also found that PTBP1 gene expression is sterol regulated
since sterol depletion reduced PTBP1 expression and this was
reversed by sterol loading. These results are consistent with recent
reports demonstrating that PTBP1 protein is up-regulated in vivo in
LDLR
2/2 mice fed a Western versus chow diet [33]. Further-
more, PTBP1 knock-down eliminated sterol induced regulation of
alternative splicing of LDLR, HMGCS1 and MVK. These findings,
together with the down regulation of PTBP1 gene expression by
sterol depletion, are consistent with the likelihood that regulation
of PTBP1 mediates sterol-induced changes in the magnitude of
alternative splicing of LDLR, HMGCS1, and MVK. Although
PTBP1 knock-down reduced PCSK9 8(2)/8(+), it did not
influence sterol induced change in this ratio; in addition, PTBP1
does not appear to regulate HMGCR, suggesting the involvement
Figure 8. Interaction between genetic and non-genetic regulators of HMGCR and LDLR alternative splicing. A) Correlation of
%HMGCR13(2) expressed after 24 hour treatment with 2.0 mM simvastatin versus sham buffer (baseline value) in 134 immortalized lymphoblast cell
lines split by rs3846662 genotype. The p-value indicates that the interaction between %HMGCR13(2) and rs3846662 genotype was statistically
significant. B and D) %HMGCR13(2) and %LDLR12(2) at baseline conditions and after statin treatment split by rs3846662 or rs688 genotype
respectively. P-values were calculated using a two-tailed paired t-test. Values shown are mean 6 s.e.m. C) Correlation of %LDLR12(2) expressed after
treatment with simvastatin versus after treatment with placebo (baseline value) in 251 immortalized lymphoblast cell lines. A dominant genetic
model was applied since C/T and T/T cell lines behaved identically.
doi:10.1371/journal.pone.0019420.g008
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consistent with previous reports that PTBP1 knock-down did not
alter either HMGCR or SREBP2 transcript levels [16]. Given the
fact that PTBP1 has been shown to regulate alternative splicing of
numerous other genes not previously implicated in cholesterol
metabolism [13,14,15], our findings raise the possibility that sterols
influence alternative splicing on a more global scale beyond the
genes described here. However, in the absence of changes in
transcriptional response, the physiological effects of changes in
alternative splicing may be minimal.
Although many of the coordinated changes in the relative ratios
of alternatively spliced to full-length transcripts can be attributed
at least in part to PTBP1 mediated changes in alternative splicing,
we found that splice variant specific regulation of mRNA half-life
also occurs. The reduction in %HMGCR13(2) with sterol
depletion is likely due to a combination of both transcript-specific
changes in half-life and direct effects on exon 13 skipping. We
showed that sterol depletion specifically reduced the half-life of the
HMGCR13(2) transcript, but had no effect on the half-life of
HMGCR13(+). However, we also found that the absolute level of
HMGCR13(2) drops while HMGCR13(+) increases within 30
minutes of statin exposure, an effect not likely attributable to
changes in transcript stability. In addition, as described further
below there was an interaction between statin-induced changes in
%HMGCR13(2) and rs3846662, a SNP that directly regulates
exon 13 skipping, demonstrating that there are also sterol-induced
changes in the process of alternative splicing. Although splice
variant-specific changes in mRNA stability and direct regulation of
alternative splicing can each contribute to the overall changes in
the relative abundance of alternatively spliced transcripts,
regulation at the level of mRNA stability was only identified in
two of the transcripts studied, HMGCR13(2) and LDLR4(2),
while changes in alternative splicing were evident for all six
transcripts studied, consistent with a pathway level effect.
Using a repository of immortalized lymphoblast cell lines, we
demonstrated that the magnitude of sterol-induced changes in
both suppression and induction of HMGCR and LDLR percent
alternatively spliced transcripts varied widely among individual
cell lines, but that these changes were strongly correlated among
the cell lines. Although we previously reported that HMGCR13(+)
and 13(2) were induced to a similar degree in 172 immortalized
lymphoblast cell lines incubated with either 1.8 or 14.5 mM
activated simvastatin in the presence of 10% FBS (24 hours) [4],
additional data (total n=185) revealed that the 13(2) transcript
was induced slightly less (5.1%, p=0.039) than the 13(+)
transcript. Since these cells were exposed to identical incubation
conditions, variation in response suggests that there is a genetic
component in the regulation of alternative splicing. Cis-acting
SNPs in both HMGCR and LDLR, rs3846662 and rs688, have
been shown to regulate exon 13 and exon 12 skipping respectively
[3,6]. Notably, there was evidence for a strong interaction between
genetic and sterol regulation of alternative splicing since sterol
depletion blunted the relationship between rs3846662 and
%HMGCR13(2), and rs688 with %LDLR12(2), suggesting that
these SNPs influence the mechanism by which sterols regulate
alternative splicing. On the basis of these findings, these SNPs
would be predicted to be more strongly associated with inter-
individual variation in ambient levels of plasma LDL-cholesterol
than with changes induced by statin treatment. Indeed, this
appears to be true since neither rs3846662 nor rs688 have been
associated with statistically significant changes in LDL-cholesterol
after statin treatment despite their association with baseline levels
of LDL-cholesterol [3,6,34,35,36,37,38]. A SNP by sterol
interaction is consistent with the finding of sterol-induced changes
in HMGCR alternative splicing in the HepG2 cell line, which is
heterozygous for the minor allele of rs3846662. However, the
HepG2 cell line is homozygous for the rs688 ‘‘C’’ allele, which,
based on results in lymphoblast cell lines with this genotype, would
predict lack of statin suppression of %LDLR12(2), in direct
contrast to our findings. This inconsistency may reflect cell type
specific differences in the genetic regulation of LDLR exon 12
skipping.
HMGCR and LDLR transcriptional responses to sterols are
coordinately regulated by SREBP, as indicated by the correlation
of their changes in response to statin in our lymphoblast cell lines
(p=0.03, n=24). The lack of correlation between fold changes in
either total HMGCR or LDLR gene expression with
%HMGCR13(2), %LDLR12(2) or %LDLR4(2) indicates that
the molecular mechanisms underlying variation in the transcrip-
tional regulation of these genes in response to sterol depletion do
not also influence changes in alternative splicing. These results
demonstrate that variation in transcriptional regulation is
independent of variation in pre-mRNA splicing. The finding that
changes in HMGCR exon 13 skipping occur prior to changes in
gene transcription provides further evidence of independent
control. In the case of prolonged exposure to extreme cholesterol
depletion, such as a 24 hour incubation with statin in the absence
of exogenous cholesterol, this small shift in pre-mRNA splicing to
generate more 13(+) versus 13(2) transcript may initially help
correct for small imbalances in cholesterol homeostasis prior to the
stimulation of a robust transcriptional response. Furthermore, the
fact that this was seen only with HMGCR is consistent with the
extensive degree to which HMGCR activity is regulated [20], and
indicates that HMGCR alternative splicing is subject to additional
forms of regulation.
We have shown that alternative splicing contributes to
coordinate regulation of genes involved in cholesterol homeostasis,
including the two key regulatory genes HMGCR and LDLR. This
effect is influenced by cis-acting SNPs that blunt the suppression of
alternative splicing in response to sterol depletion. Our findings
indicate that alternative splicing augments the robust transcrip-
tional response generated by changes in cellular cholesterol status,
and contributes to cellular cholesterol homeostasis under condi-
tions of variation in sterol availability, such as statin treatment.
Methods
Cell Exposures
HepG2 cells were grown in MEM supplemented with 1%
nonessential amino acids, 1% sodium pyruvate and 10% heat
inactivated fetal bovine serum (FBS) (Hyclone). Immortalized
lymphoblast cell lines were derived from the Cholesterol and
Pharmacogenetics clinical trial [39], and grown in RPMI 1640
media supplemented with 10% FBS, 500 U/ml penicillin/
streptomycin, and 2 nmol/L GlutaMAX [4]. IMR-90 cells were
grown in high glucose DMEM supplemented 2 nmol/L Gluta-
MAX and 10% FBS. All culture media and supplements were
obtained from Invitrogen unless otherwise indicated, and all
cultures were maintained at 37uC with 5% CO2. Simvastatin was
provided as a gift from Merck (Whitehouse Station, NJ) and was
converted into 99% of the activated form (beta-hydroxy
simvastatin acid) as previously described [4]. LDL-cholesterol
was isolated from 250 ml of plasma from a single individual as
previously described [40] using written informed consent and with
approval by the Committee for the Protection of Human Subjects
at Children’s Hospital and Research Center Oakland. LDL-
cholesterol concentration was calculated by the Friedewald
equation. Cells were exposed to either conditions of sterol
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ed with 10% lipoprotein deficient serum (LPDS) and simvas-
tatin (concentration varied by experiment), or sterol loading,
defined as 24 hour incubation in media supplemented with
10% LPDS and either 50 mg/ml LDL-cholesterol or 1 mg/ml
25-hydroxycholesterol.
Animal studies
Wild caught feral adult male St. Kitts vervets (Cercopithecus
aethiops sabaeus), also called African green monkeys [41] were
studied in two separate experiments. Because the plasma
cholesterol response to dietary cholesterol varies widely among
individuals, plasma cholesterol response to a 4 week challenge with
a diet containing 35% of energy as saturated fat and 0.4 mg/kcal
of dietary cholesterol was assessed for each animal. A 4 month
washout with monkey chow diet followed this initial diet challenge.
In the first experiment, animals were fed a diet with no added
cholesterol (see Rudel et al. [42] for diet composition) for 22 weeks,
n=20. Animals were then fed for 19-weeks with the same diet
supplemented with 0.6 mg/kcal cholesterol with either 35% of the
energy as monounsaturated fat (n=10) or saturated fat (n=10).
Liver biopsies were surgically collected via a midline laparotomy
before and after cholesterol feeding, and tissues were stored at
280uC until analysis. A portion of frozen tissue was taken,
weighed, and liver lipid concentrations were determined after lipid
extraction using the enzymatic methods previously described [43].
One animal died before liver biopsies were collected and data
from a second animal was omitted since it demonstrated abnormal
transcriptional up-regulation of HMGCR and LDLR after choles-
terol feeding. In the second experiment animals were fed a diet
containing 35% of energy as monounsaturated fat supplemented
with 0.002, 0.2 or 0.4 mg/kcal cholesterol (n=5 per diet), and
liver biopsies were collected after 10-weeks. All procedures were
approved by the Wake Forest University Animal Care and Use
Committee through protocols A04-048 and A10-024. All efforts
were made to minimize suffering using the appropriate anesthetic
and analgesic agents. Animals were routinely monitored by
veterinarians for all medical and dental conditions, with
appropriate treatments administered by specialists.
Liver tissue was snap frozen in liquid nitrogen at the time of
collection and was stored at 280uC until processed for RNA
extraction. Liver RNA was extracted with Trizol (Invitrogen), and
RNA concentration and integrity was verified by A260/280
reading and gel electrophoresis. Expression of alternatively spliced
transcripts was verified by RT-PCR and DNA sequencing; primer
sequences are listed in Table S1. Positively identified splice
variants were quantified by qPCR. Baseline quantities of each
transcript were calculated as the average of experiment 1 animals
collected before cholesterol feeding (n=18) and experiment 2
animals after 0.002 mg/kcal cholesterol feeding (n=5). Transcript
fold changes with cholesterol feeding for each individual were
calculated as the transcript quantity after cholesterol feeding
divided by the averaged baseline value (n=28). Since there were
no consistent statistically significant differences in cholesterol-
induced changes in %HMGCS1 2(2), %MVK4(2), %LDLR4(2),
%LDLR12(2) or %PCSK9 8(2) among the three cholesterol
doses, the data for all doses were combined for each of these splice
variants.
siRNA transfection
PTBP1 knock-down was achieved by 18 hour transfection of
2.5610
5 HepG2 cells/well in 6-well plates with 12.5 pmole
Silencer Select siRNA (Applied Biosystems) using pSPORT-
NeoFX transfection agent (Applied Biosystems) following the
manufacturer’s protocol. Cells were exposed in replicate to either
the PTBP1 siRNA duplex, the Silencer Select Negative Control
#1 (Applied Biosystems), pSPORTNeoFx transfection agent only,
or no additions to ensure that changes in alternative splicing with
knock-down were specific to the reduction of PTBP1. Knock-down
was confirmed by qPCR and Western blot incubated with a
monoclonal mouse anti-PTB antibody (Invitrogen) and GAPDH
(D-6) mouse monoclonal antibody (Invitrogen). Protein band
intensity was quantified on the Alpha Imager TM.
Transcript quantification
RNA was extracted using the Qiagen RNAeasy (Qiagen) mini-
kit with QIAshredders, and 5 mg of RNA was reverse transcribed
into cDNA using the Applied Biosystems cDNA archive kit.
Specific qPCR assays were designed using Primer3 [44]. For all
assays, either one primer (Elim Biopharmaceuticals) or the
fluorescent probe (Applied Biosystems) was designed to directly
overlay the site of alternative splicing, for example the exon 3 to
exon 5 splice junction in the case of LDLR4(2). All transcripts
were quantified in both human and monkey samples with either
TaqMan or SYBR Green assays using TaqMan or SYBR
Universal Master Mix (Applied Biosystems) with primer sequences
listed in Table S1. PCSK9 and HMGCR splice variants were
quantified using the assays previously described [4,5]. The
remaining splice variants were quantified using SYBR Green
Master Mix, with dissociation curves run at the end of each
reaction to ensure the generation of a single PCR amplicon. All
reactions were performed in triplicate using 50 ng cDNA per
reaction. Absolute quantification of splice variants was performed
using a serially diluted standard containing the same sequence as
the target amplicon. The specificity of all qPCR assays was verified
by testing for detection of a standard known to contain only the
full-length transcript of a gene with the qPCR assay specific for its
corresponding alternatively spliced variant (for example,
HMGCR13(+) template with 13(2) qPCR assay). Lack of cross-
reaction in the reverse direction (for example, HMGCR13(2)
template with 13(+) qPCR assay) was also confirmed. Primer and
probe sequences are listed in Table S2. CLPTM1 and SLC7A
were quantified in all samples for data normalization. For
Figure 1A only, both HMGCR13(+) and 13(2) transcripts were
amplified by PCR using the following primers, HMGCRex12.F:
tgctaagcatatcccagcctacaag and HMGCRex14.R: atgcctcctttat-
cactgcgaacc. PCR product was loaded onto an agarose gel, and
band density was quantified using the AlphaView Software 1.2.01
(Alpha Innotech).
Percent alternatively spliced mRNA was calculated as the
quantity of the splice variant divided by the quantity of the total
transcripts per gene, e.g., 1006 HMGCR13(2) divided by
[HMGCR13(2) + HMGCR13(+)]. Fold changes were calculated
as the value of the percent alternatively spliced after statin
treatment or sterol loading, divided by the percent alternative
spliced under basal culture conditions, i.e., %HMGCR13(2) with
statin + 10% LPDS divided by %HMGCR13(2) +10% FBS. All
experiments were performed in triplicate unless otherwise
indicated.
Measurement of transcript half-life
HepG2 (n=12) were first incubated for 24 hours with either
2.0 mM simvastatin + 10% LPDS or sham buffer, after which
1 mg/ml actinomycin D was added. Samples were removed at
eight time points over the course of 48 hours, and splice variants
were quantified as described above. Transcript half-life was
calculated as previously described using only time points consistent
with first order decay kinetics [45]. Half-life was calculated from
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and standard error values between statin versus sham incubated
cells. In addition, mRNA data per time point was averaged, and
half-life was calculated from the pooled data. Half-life values
measured in the averaged versus pooled data sets were not
significantly different. To determine the effects of PTBP1 on
transcript half-life, HepG2 cells were transfected with either a non-
targeting siRNA control or PTBP1 specific siRNA as previously
described, n=12. After 18 hours, 1 mg/mL actinomycin D was
added, and transcript half-life was measured as described above.
Genotyping
Rs3846662 genotyping was performed as previously described
[34]. Rs688 genotyping was performed using a fluorogenic allele-
specific amplification method (Millipore) as previously described
[6]. Following amplification, fluorescence was read using an ABI
7900HT (Applied Biosystems) and cluster analysis performed
using SDS v2.3 software (Applied Biosystems).
Statistical Analyses
qPCR data were analyzed as previously described with all data
normalized to CLPTM1 and SLC7A, whose expression was
validated to be non-responsive to sterols [4]. For gene expression
quantification by qPCR, the Grubb’s test for outliers was
calculated for each three triplicate measurement. For dose
response curves, repeated measures MANOVA was used to assess
statin-induced differences between the up-regulation of the
HMGCR13(+) and 13(2) transcripts. Statistically significant
differences in percent alternatively spliced transcripts (HMGCR,
LDLR, HMGCS1, MVK, or PCSK9) after in vitro treatment with
simvastatin, LDL-cholesterol or 25-hydroxycholesterol were
calculated using two-tailed paired t-tests. Two-tailed paired t-tests
were also used to identify statistically significant differences in the
magnitude of change between the full length and alternatively
spliced transcripts in cholesterol versus control fed monkeys.
Correlations between %HMGCR13(2) with %LDLR12(2) and
%LDLR4(2) among statin or 25-hydroxycholesterol treated
immortalized lymphoblast cell lines were assessed by linear
regression. To test for a significant interaction between
rs3846662 with statin suppression of %HMGCR13(2), multivar-
iate regression models were created with %HMGCR13(2) after
statin as the dependent variable, and %HMGCR13(2) at baseline
as the independent variable with adjustment for rs3846662 and an
interaction between %HMGCR13(2) at baseline with rs3846662.
A similar model was generated to assess interaction between rs688
and statin suppression of %LDLR12(2). All statistical analyses
were performed using JMP 7.0.1 (SAS Institute).
Supporting Information
Figure S1 Change in hepatic total cholesterol and
cholesterol ester is correlated with change in percent
LDLR alternative splicing. Hepatic total cholesterol and
cholesterol ester were measured in liver biopsies obtained from
African green monkeys with (n=19) and without (n=14)
cholesterol supplementation. Percent change in hepatic lipids for
each cholesterol fed animal were calculated from the average of all
control fed animals, and values were adjusted for the change in total
plasma cholesterol as well as the predominant fat (monounsaturated
versus saturated) in each diet to account for differences in response
due to variation in the amount of cholesterol supplementation (0.2,
0.4 and 0.6 kcal/g). Direct correlation in inter-individual variation
in the residuals of percent change in hepatic lipids with change in
alternative splicing was assessed in JMP 7.0.1. Animals who
experienced greater increases in hepatic total cholesterol (A)a n d
cholesterol ester (B) also had greater increases in %LDLR12(-).
Similar relationships were seen with other splice variants, but did
not achieve statistical significance. There was no relationship
between change in hepatic free cholesterol and %LDLR12(-).This
lack of relationship is consistent with the fact that levels of hepatic
free cholesterolwere notelevated inastatisticallysignificantmanner
after cholesterol feeding (3.060.1 mg/g liver no cholesterol versus
4.260.5 mg/g liver with cholesterol, p=0.07), compared to
changes in hepatic cholesterol ester (2.460.5 mg/g liver no
cholesterol versus 15.662.7 mg/g liver with cholesterol,
p,0.001). **Scale reflects residual percent change values after
adjustment as described above.
(TIF)
Figure S2 Effect of PTBP1 knock-down on transcript
half-life. Actinomycin D (1mg/ml) was added to HepG2 cells
after 18hr transfection with either PTBP1 Silence Select siRNA or
a non-targeting siRNA control, n=8. All values shown are mean
6 s.e.m. *p,0.05, half-life is significantly different between cells
transfected with the non-targeting siRNA and the PTBP1 specific
siRNA.
(TIF)
Figure S3 Change in total transcript levels with PTBP1
knock-down. HepG2 cells were transfected with either a siRNA
targeted to PTBP1 or a non-targeting negative control in
duplicate. After 18 hours, incubation media was refreshed to
include either 2.0mM simvastatin + 10% LPDS or placebo buffer +
10% FBS and cells were incubated for an additional 24 hours,
n=8. Statin induced fold changes in gene expression were
calculated independently in the PTBP1 siRNA versus non-
targeting negative control samples as the value measured in the
statin incubated sample divided by the value measured in the
placebo incubated sample. All values shown are mean 6 s.e.m.
(TIF)
Table S1 Primer and probe sequences used for quan-
titative real time PCR to detect specific splice variants.
All assays with probe sequences listed were used as TaqMan
assays, assays without a probe sequence were used as SYBR Green
assays.
(DOC)
Table S2 Primer sequences used to detect expression of
alternatively spliced transcripts in the African Green
Monkey.
(DOC)
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